SG/CALL/BRISTOL-MYERS SQUIBB/65/0.1/17.01.25 | Market Closed - Deutsche Boerse AG 20:39:48 20/06/2024 BST | ||
| 0.01 EUR | +42.86% |
|
| 1 month | -33.33% | ||
| 3 months | -88.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 0.01 | +42.86% |
| 19/06/24 | 0.007 | 0.00% |
| 18/06/24 | 0.007 | -30.00% |
| 17/06/24 | 0.01 | 0.00% |
| 14/06/24 | 0.01 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 08:39 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ86UD |
| ISIN | DE000SQ86UD4 |
| Date issued | 16/02/2023 |
| Strike | 65 $ |
| Maturity | 17/01/2025 (211 Days) |
| Parity | 10 : 1 |
| Emission price | 1.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.33 € |
|---|---|
| Lowest since issue | 0.006 € |
| Spread | 0.01 € |
| Spread % | 50.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.04
USD
Average target price
53.19
USD
Spread / Average Target
+29.62%
- Stock Market
- Warrants
- Warrant
